Table 1.
Patient characteristics
| CHARACTERISTIC | |
|---|---|
| Age: Median (range) |
61years (46–74 years) |
| Male |
26 (58%) |
| Female |
19 (42%) |
| Significant Bone disease1 |
23 (51%) |
| Time following completion of treatment |
11months (median) |
| |
(range 3–149 months) |
| Previous ASCT2 |
42 (93%) |
| Previous orthopaedic surgery |
6 (13%) |
|
Current therapies |
|
| Maintenance treatment |
9 (20%) |
| • Lenalidomide |
1 |
| • Interferon |
2 |
| • Thalidomide |
6 |
| Regular analgesia | 11 (24%) |
Details are given of patient characteristics for the 45 patients who completed baseline screening.
1 with one or more of the following: bone pain, vertebral collapse, fractures.
2 autologous stem cell transplantation.